A new sub-study from the CoreValve U.S. Trial published in February's issue of JACC: Cardiovascular Interventions marks a step closer to a model for deciding what extreme surgical risk patients should NOT undergo Transcatheter Aortic Valve Replacement (TAVR).
While a majority of extreme-risk patients did see significant positive change in disease-specific, general health and quality-of-life metrics following TAVR, a large minority—39 percent of patients—had a poor outcome post-TAVR.